Telum Therapeutics develops novel antimicrobial therapies targeting multidrug-resistant hospital-acquired and ventilator-associated bacterial pneumonia.
| Date | Round | Amount |
|---|---|---|
| Jul 2026 | Series A Telum Therapeutics completed an 18 million euro Series A to advance its lead antimicrobial programme through Phase 1 clinical development. AMR Action Fund led the round with new investor Inveready and existing backers. | $20.7M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.